UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 861177
NEW YORK, NY
Position in SLS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$4,035,426
New position
Shares Held
273,403
first reported quarter
Ownership
0.135%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#30
of 192 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 45%
Shared 0%
None 55%
Position in Biotechnology
Healthcare · as of Jun 30, 2026UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,443,898,601 across 206 Biotechnology names. SLS ranks #70 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,086,683 | $1,533,248,041 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
716,560 | $446,803,817 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
727,848 | $219,104,078 | |
| 4 | INCY |
Incyte Corp
|
1,508,720 | $171,028,494 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
912,335 | $170,862,094 | |
| 6 | INSM |
INSMED Inc
|
1,335,071 | $142,345,265 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
1,454,672 | $115,340,938 | |
| 8 | MRNA |
Moderna, Inc.
|
1,521,849 | $106,575,080 |
All Filings in SLS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,035,426 | 273,403 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||